<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02297984</url>
  </required_header>
  <id_info>
    <org_study_id>H1583-660145</org_study_id>
    <nct_id>NCT02297984</nct_id>
  </id_info>
  <brief_title>Serum Neuroglobin and HIF-1α in Acute Ischemic Stroke</brief_title>
  <official_title>Changes of Serum Neuroglobin and HIF-1α Concentrations in Early-phase of Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 6th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuroglobin has shown rich neuroprotective effects against cerebral ischemia and hypoxia, and&#xD;
      therefore has the potential to impact outcomes after acute ischemic stroke. Hypoxia inducible&#xD;
      factor (HIF)-1α is neuroprotective in several models of experimental brain injury and is&#xD;
      increased in brain after acute cerebral infarction in humans and experimental animals.The&#xD;
      investigators sought to examine the changes in serum neuroglobin and HIF-1α concentrations in&#xD;
      patients with acute ischemic stroke during the initial 96-h period after stroke and assessed&#xD;
      the relation between them and the relation of them to prognosis of such patients with acute&#xD;
      ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Modified Rankin Scale scores</measure>
    <time_frame>3 months</time_frame>
    <description>0 = No symptoms; 1 = No significant disability. Able to carry out all usual activities, despite some symptoms; 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 = Moderate disability. Requires some help, but able to walk unassisted; 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 = Dead.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glasgow Outcome Scale scores</measure>
    <time_frame>3 months</time_frame>
    <description>Glasgow Outcome Scale 1 = death; Glasgow Outcome Scale 2 = vegetative state; Glasgow Outcome Scale 3 = severe neurological deficit; Glasgow Outcome Scale 4 = mild neurological deficit and Glasgow Outcome Scale 5 = premorbid level of functioning or completely recovery.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Acute ischemic stroke</arm_group_label>
    <description>Patients who suffered from acute ischemic stroke within 12 hours for the first time before entry into the study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The patient group comprised 24 male and 16 female. Their age ranged from 42 to 76 years.&#xD;
        Locations of infarct, as evidenced by radiologic and neurologic symptoms or signs, included&#xD;
        the territories of the middle cerebral artery (13 cases), the posterior cerebral artery (9&#xD;
        cases) the anterior cerebral artery (8 cases), vertebrobasilar area (7 cases), and&#xD;
        watershed area (3 cases with cortical and subcortical low densities crossing typical&#xD;
        vascular territories).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of acute ischemic stroke&#xD;
&#xD;
          -  Admission within 12 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lacunar infarction&#xD;
&#xD;
          -  Cerebral hemorrhagic infarction&#xD;
&#xD;
          -  Epilepsy or epileptic persons&#xD;
&#xD;
          -  History of neurological diseases, myocardial infarction, renal and hepatic&#xD;
             abnormalities and metabolic diseases&#xD;
&#xD;
          -  Contraindications to antiplatelet treatments&#xD;
&#xD;
          -  Serial blood samples could not be obtained&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Years</minimum_age>
    <maximum_age>76 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lixia Xue, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai 6th People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Sixth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>August 8, 2020</last_update_submitted>
  <last_update_submitted_qc>August 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 6th People's Hospital</investigator_affiliation>
    <investigator_full_name>Hao Chen</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Neuroglobin</keyword>
  <keyword>HIF-α</keyword>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

